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A prostacyclin analog beraprost sodium attenuates radiocontrast
media-induced LLC-PK1 cells injury
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A prostacyclin analog beraprost sodium attenuates radiocon-
trast media-induced LLC-PK1 cells injury.
Background. We previously reported that the apoptotic in-
jury in a porcine renal tubular cell line LLC-PK1 cells induced
by radiographic contrast media is attenuated by dibutyl cyclic
adenosine monophosphate (cAMP) in a manner dependent on
protein kinase A (PKA). The present study was designed to
determine whether the elevation of endogenous cAMP with
beraprost sodium, a prostacyclin analog, reduces the contrast
material-induced renal tubular injury.
Methods. The cell injury was induced by the exposure to iover-
sol for 30 minutes followed by further incubation for 24 hours in
the absence of the contrast medium, and assessed by propidium
iodide uptake and WST-8 assay. Apoptosis was determined by
annexin V stain and DNA electrophoresis. Caspase activity was
assessed by the enzymatic degradation of specific substrate pep-
tides. Bax and bcl-2 mRNA expression were determined by re-
verse transcription-polymerase chain reaction (RT-PCR). The
phosphorylation of cAMP-responsive element binding protein
(CREB) was measured by an immunofluorescent method.
Results. Beraprost sodium (10 to 1000 nmol/L) attenuated
concentration dependently the ioversol-induced decrease in cell
viability, in which the protective effect of beraprost sodium
was dependent on the elevation of cellular cAMP content. The
phosphorylation of CREB was enhanced by beraprost sodium
in PKA-dependent manner. In addition, beraprost sodium re-
versed the ioversol-induced increase in bax mRNA with a con-
comitant decrease in bcl-2 mRNA and subsequent activation
of caspase-3 and -9, thereby resulting in the inhibition of the
nuclear damage.
Conclusion. Beraprost sodium reversed the contrast
media-induced renal tubular cells in culture by activating
cAMP/protein kinase A–dependent phosphorylation of CREB
and subsequent enhancement of bcl-2 expression.
Nephrotoxicity is a major complaint after radiographic
examination with iodinated contrast materials. Although
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the precise mechanisms underlying the contrast media-
induced nephrotoxicity remain unknown, the decrease
in renal blood flow and the direct degenerative action
on renal tubular epithelial cells are considered to be im-
plicated in the etiology of contrast media nephropathy
[1, 2].
We have recently shown in a porcine renal tubular
cell line LLC-PK1 cells that a variety of radiographic
contrast media induce caspase-dependent apoptotic cell
death [3]. In addition, the cell injury induced by the
contrast medium are reversed by dibutyryl cyclic adeno-
sine monophosphate (cAMP) (DBcAMP), a membrane-
permeable cAMP analogue, in a manner dependent on
the activity of protein kinase A (PKA) [3]. It has been
demonstrated that cAMP signaling cascade plays an im-
portant role in regulation of apoptotic injury in a variety
of cells [4–6]. In the present study, we investigated the
effect of the agent that stimulates the synthesis of en-
dogenous cAMP on the renal tubular cell injury induced
by ioversol, a nonionic iodinated radiographic contrast
medium.
Prostacyclin receptor is coupled to the stimulatory G
protein to enhance cAMP production [7]. The prostacy-
clin receptor distributes to the glomerular cells, endothe-
lial cells, distal tubules, and collecting ducts in human
kidney, as shown by the immunohistochemical study us-
ing polyclonal antibody against prostacyclin receptor and
the in situ hybridization technique [8]. A number of stud-
ies have demonstrated the protective effect of prosta-
cyclin in a variety of models for renal injury, including
the ischemic acute renal failure in dogs [9]. Although
the protective effect of prostacyclin is considered to be
due primarily to the vasodilatory action, the direct pro-
tective action on renal epithelial cells is demonstrated
in hypoxia/reoxygenation injury in a primary culture of
rat proximal tubular epithelial cells [10]. However, lit-
tle is known about the effectiveness of prostacyclin on
the renal injury caused by radiographic contrast me-
dia. Therefore, the effect of beraprost sodium, a stable
and orally active prostacyclin analog used clinically for
the therapy of chronic obstructive arterial diseases and
primary pulmonary hypertension [11], on the contrast
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material-induced injury was investigated in LLC-PK1
cells.
METHODS
Materials
Ioversol (Optiray 350) (350 mg iodine/mL), a non-
ionic and monomeric iodinated radiographic contrast
medium, the osmolality and viscosity of which are 712
mOsm/kg and 8.2 mPa/second, respectively, was obtained
from Yamanouchi Pharmaceutical Co., Ltd. (Tokyo,
Japan). Fluorescence-labeled caspase substrates such as
Ac-DEVD-AMC for caspase-3, Ac-LEHD-AMC for
caspase-9, and Ac-IETD-AMC for caspase-8 were pur-
chased from Alexis Biochemicals (San Diego, CA, USA).
Caspase inhibitors, including zDEVD-fmk (a caspase-
3 specific inhibitor), zIETD–fmk (a caspase-8 specific
inhibitor), and zLEHD–fmk (a caspase-9 specific in-
hibitor) were obtained from Calbiochem (San Diego, CA,
USA). 3-isobutyl-1-methylxanthine (IBMX) and DB-
cAMP were purchased from Sigma (St. Louis, MO, USA).
H89, a PKA inhibitor, was purchased from Seikagaku
Co., Ltd. (Tokyo, Japan). Beraprost sodium was kindly
donated from Toray Industries, Inc. (Tokyo, Japan).
Cell culture
A porcine proximal renal tubular cell line LLC-PK1
cells (American Type Culture Collection, Rockville, MD,
USA) were grown in 75 cm2 flask (Corning, Inc., Corning,
NY, USA) and maintained in Medium 199 (ICN Biomed-
icals, Inc., Aurora, OH, USA), supplemented with 10%
fetal bovine serum (FBS) (JRH Bioscience, Inc., Lenexa,
KS, USA), 60 lg/mL penicillin (Sigma) in an atmosphere
of 5% CO2 in air at 37◦C. Then, the cells were seeded on
24-well plastic plates (Falcon) (Becton Dickinson Co.,
Ltd., Franklin Lakes, NJ, USA) at a density of 1.0 × 104
cells/cm2 and cultured at 37◦C for 24 hours.
Cell viability
Cells were transiently (30 minutes) exposed to iover-
sol (100 mg iodine/mL, final osmolality 421 mOsm/kg,
pH 7.45) and the medium was washed twice with freshly
prepared Krebs-Ringer solution, then the cells were in-
cubated in serum-free culture medium for 24 hours at
37◦C in 5% CO2-95% air. To demonstrate roles of PKA
in the action of beraprost sodium, a PKA inhibitor H89
(10 lmol/L) was added 1 hour before, while beraprost
(10 to 1000 nmol/L) was included 30 minutes before,
the treatment with contrast media. The cell viability
was assessed by the mitochondrial activity to reduce
WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-
5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt]
to formazan [12], or the cellular uptake of propidium
iodide. For WST-8 assay, cells were incubated at 37◦C
for 1 hour in 210 lL of serum-free medium contain-
ing 10 lL of assay solution (Cell Counting Kit-8) (Do-
jindo Laboratory, Kumamoto, Japan). Aliquots of the
incubation medium wwere transferred to 96-well mi-
croplate (Corning, Inc.), and absorbance was measured
at 450 nm with the reference wavelength of 620 nm us-
ing a microplate reader (Immuno Mini NJ-2300) (Inter
Med, Tokyo, Japan). For propidium iodide uptake, cells
were cultured on 8-chamber plastic slides (Iwaki, Asahi
Techno Glass Co., Tokyo, Japan) at a density of 1.0 ×
104 cells/chamber, then washed twice with phosphate-
buffered saline (PBS), and incubated further for
30 minutes in the dark in 100 lL buffer containing
2 lL propidium iodide (Medical & Biological Lab Co.,
Ltd., Nagoya, Japan). Then, the cells were washed twice
with buffer and visualized using a fluorescent micro-
scope (BX51) (Olympus, Tokyo, Japan) under × 100
magnification.
Assessment for apoptosis
Apoptosis was assessed by annexin V stain by using
Mebcyto apoptosis kit (Medical & Biological Lab Co.,
Ltd.). LLC-PK1 cells were cultured for 24 hours on 8-
chamber plastic slides at a density of 2.0 × 104 cells/
chamber. Then, the cells were washed twice with PBS,
and incubated for 30 minutes in the dark in 100 lL buffer
containing 10 lL fluorescent isothiocyanate-labeled an-
nexin V. Cells were washed twice thereafter with an ex-
cessive amount of PBS and visualized with a fluorescent
microscope under × 100 magnification.
DNA electrophoresis
The internucleosomal DNA fragmentation was as-
sessed by an agarose gel electrophoresis, as described
by Duke, Chervenak, and Cohen [13]. Briefly, LLC-PK1
cells were trypsinized and centrifuged at 150g for 10 min-
utes. The resultant pellets were dissolved in 1 mL of lysis
solution and centrifuged again at 10,000g for 20 seconds
at 4◦C, then the pellets were resuspended in 200 lL of en-
zyme reaction solution. To the suspension, 10 lL protease
solution was added and incubated at 37◦C for 1 hour, then
sodium iodide was included. DNA was extracted with
isopropanol. The isolated DNA was then treated with
10 lg RNase A (ICN Biomedicals, Inc.) at 37◦C for
30 minutes, and subjected to electrophoresis with 2%
agarose gel. After electrophoresis, DNA was visualized
by staining with ethidium bromide.
Assay for caspase activity
Caspase activities were determined fluorometrically
by the degradation of the peptide substrates specific for
caspase-3 (DEVD-AMC), caspase-8 (IETD-AMC), or
caspase-9 (LEHD-AMC), based on the protocols for
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the caspase activity assay kit (BioVision, Inc., Moun-
tain View, CA, USA). Cells were centrifuged at 150g for
10 minutes, and the resultant pellets were suspended in
1 mL lysis buffer (BioVision, Inc.) and subjected to cas-
pase activity assay. The reaction was started by incubat-
ing the enzyme extracts with each caspase substrate for
10 minutes in the absence or presence of 10 lmol/L
caspase inhibitors, including zDEVD-fmk for caspase-3,
zIETD-fmk for caspase-8, and zLEHD-fmk for caspase-
9. After centrifugation at 10,000g for 10 minutes, the
concentration of the AMC (7-amino-4-methylcoumarin)
liberated into the supernatant was determined fluoro-
metrically at an excitation wavelength of 380 nm and
an emission wavelength of 460 nm by using a fluores-
cence microplate reader (MTP-650FA) (Corona Electric
Co., Ltd., Ibaragi, Japan). The protein concentration was
measured according to the method of Bradford [14]. The
caspase activity was expressed as nmol of AMC produced
per mg protein.
Reverse transcription-polymerase chain reaction
(RT-PCR)
The mRNA was isolated from LLC-PK1 cells us-
ing a Quick preparation micro mRNA purification kit
(Amersham Biosciences UK Limited, Buckinghamshire,
UK). Briefly, cells were homogenized with 0.6 mL ex-
traction buffer, and mixed with 0.8 mL elution buffer.
After centrifugation at 10,000g for 1 minute, the su-
pernatant was applied to the oligo(dT)-cellulose, and
washed with a high-salt buffer, followed by a low-salt
buffer. The mRNA was eluted with the elution buffer,
and quantified from the absorbance at 260 nm. The
mRNA solution was diluted with 20 lL RNase-free wa-
ter, and cDNA was synthesized by using a first-strand
cDNA synthesis kit (Amersham Biosciences). A 25 lL
aliquot of samples containing cDNA (corresponding to
50 ng of mRNA), 10 pmol/lL of each oligonucleotide
primer, 2.5 mmol/L of desoxynucleoside triphosphate
(dNTP) and 5 U/lL of Taq polymerase (Nippon Gene,
Co., Ltd., Tokyo, Japan) was subjected to RT-PCR. Am-
plification was carried out for 30 cycles (denaturation
at 94◦C for 30 seconds, annealing at 60◦C for 30 sec-
onds, and elongation at 72◦C for 30 seconds), followed
by an additional polymerization at 72◦C for 5 minutes,
using a Program Temp Control System PC-707 (Astec,
Co., Ltd., Fukuoka, Japan). The oligonucleotide primers
for bcl-2, bax and b-actin were designed based on the
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Fig. 1. Protective effect of beraprost sodium against the ioversol-induced apoptotic injury in LLC-PK1 cells and its reversal by a protein kinase
A (PKA) inhibitor H89. Cells were exposed to 100 mg iodine/mL ioversol for 30 minutes, followed by incubation for 24 hours in the absence of
ioversol. H89 (10 lmol/L) was added 1 hour before, while beraprost sodium (1 lmol/L) was included 30 minutes before ioversol treatment and
included throughout the experiment. Cell injury was determined by propidium iodide (PI) uptake, while apoptosis was assessed by annexin V stain.
Cells were visualized under a fluorescent microscopy (×100 magnification). Data were obtained from at least three independent experiments. (A)
Control. (B) At 24 hours after 30-minute exposure to ioversol (100 mg iodine/mL). (C) Ioversol + beraprost sodium (1 lmol/L). (D) Ioversol +
beraproat sodium + H89 (10 lmol/L).
sequences described by Rey et al [15] and Kim et al
[16], respectively. The sequences of PCR primers were as
follows: 5′-AGCGTCAACGGGAGATGTC-3′ (sense)
and 5′-GTGATGCAAGCTCCCACCAG-3′ (antisense)
for bcl-2; 5′-CAGCTCTGAGCAGATCATGAAGACA
-3′ (sense) and 5′-GCCCATCTTCTTCCAGATGGTG
AGC-3′ (antisense) for bax; and 5′-TGAGACCTTCAA
CACGCCG-3′ (sense) and 5′-ATGGTGATGACCTGC
CCGTC-3′ (antisense) for b-actin. The primers were
purchased from Sigma Genosys Japan Co., Ltd. (Sap-
poro, Japan). The PCR products were subjected to
electrophoresis on 2% agarose gel, and the DNA was
visualized by staining with ethidium bromide under ul-
traviolet irradiation. The intensities of the PCR products
were semiquantified densitometrically by using Alpha
Imager 2200 (Alpha Innotech Corporation, San Lean-
dro, CA, USA). The mRNA for b-actin was used as the
standard.
Assay for cAMP
The concentration of cAMP in LLC-PK1 cells was mea-
sured, as described previously [17]. Briefly, cells were
incubated for 20 minutes with various concentrations
of beraprost sodium in the presence of 0.5 mmol/L 3-
isobutyl-l-methylxanthine (IBMX) to prevent the degra-
dation of cAMP produced. The reaction was terminated
by the addition of 1 mL ice-cold 0.4 N perchloric acid.
Cells were homogenized, and centrifuged at 10,000g for
10 minutes. The cAMP content was determined by an en-
zymatic immunoassay using a cAMP enzyme immunoas-
say kit (Amersham Biosciences).
Immunofluorescent stain for phosphorylated cAMP
responsive element binding protein (pCREB)
The immunofluorescent stain for pCREB was carried
out according to the method of Inglefield et al [18].
Briefly, cells were cultured on 8-chamber plastic slides
(Iwaki, Asahi Techno Glass Co.) at the density of 2 × 104
cells/cm2 and incubated for 24 hours. Cells were treated
with 1 lmol/L beraprost sodium or 0.3 mmol/L DBcAMP
for 20 minutes with or without prior treatment with
10 lmol/L H89 (30 minutes). To investigate the effect of
ioversol on DBcAMP-induced CREB phosphorylation,
cells were exposed to ioversol (100 mg iodine/mL) for
30 minutes, followed by further incubation for 3 hours in
the absence of ioversol. Then, the cells were treated with
0.3 mmol/L DBcAMP for 20 minutes. The chamber slides
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were rinsed with ice-cold PBS and fixed with 10% (wt/vol)
ice-cold trichloroacetic acid for 30 minutes, at −20◦C. The
specific antibody raised against Ser133 phospho-CREB
(Affinity Bioreagents, Inc., Golden, CO, USA) was di-
luted (1:50) with PBS containing 5% (wt/vol) nonfat dried
milk and 0.1% Triton X-100. Cells were incubated with
diluted antibody solution overnight in a humidified cham-
ber at 4◦C. After washing with PBS, chamber slides were
incubated at room temperature for 2 hours with fluores-
cein isothiocyanate (FITC)-labeled goat antirat IgG (1:50
dilution in PBS) (Jackson Laboratory, Bar Harbor, ME,
USA). Cells were mounted and immunofluorescence was
detected by a fluorescence microscope (BX51, Olympus)
under ×100 magnification.
Statistical analyses
Data are expressed as the mean ± SEM. Unless
otherwise indicated, data were statistically analyzed by
one-way analysis of variance (ANOVA) followed by
Dunnett’s test for multiple comparison or by Student t
test for comparison between two groups. The nonpara-
metric data were analyzed by Kruskal-Wallis test com-
bined with Steel-type multiple comparison test. Statistical
significance was defined as P < 0.05.
RESULTS
Protective effect of beraprost sodium against
ioversol-induced apoptotic injury in LLC-PK1 cells
As we reported previously [3], a transient (30 minutes)
exposure of LLC-PK1 cells to ioversol caused a delayed
injury, as assessed at 24 hours by propidium iodide up-
take (Fig. 1B). The cell injury seemed to be associated
with apoptosis, since a number of cells positively stained
with annexin V were observed (Fig. 1B). Both the in-
crease in propidium iodide stain and the number of an-
nexin V–positive cells induced by ioversol were greatly
reduced by beraprost sodium (1 lmol/L) (Fig. 1C). On
the other hand, the nuclear damage determined by DNA
electrophoresis was marked after a transient exposure
to ioversol (Fig. 2, lane 2). The ioversol-induced DNA
ladder was attenuated by 1 lmol/L beraprost sodium
(Fig. 2, lane 3). These effects of beraprost sodium were
all reversed by 10 lmol/L H89, a PKA inhibitor [19]
(Figs. 1D and 2, lane 4).
Subsequently, the concentration-dependency in the
protective effect of beraprost sodium was examined.
As shown in Figure 3A, beraprost sodium reversed the
ioversol-induced loss of cell viability determined by WST-
8 assay in a concentration-dependent manner. In ac-
cordance with the protective action, beraprost sodium
produced a concentration-dependent increase in cAMP
content in LLC-PK1 cells (Fig. 3B). On the other hand,
the toxic effect of ioversol was time-dependent, in which
the significant injury was observed already at 3 hours
M 1 2 3 4 5
Fig. 2. Inhibition by beraprost sodium of the ioversol-induced DNA
fragmentation and its reversal by H89 in LLC-PK1 cells. Cells were
exposed to ioversol (100 mg iodine/mL) for 30 minutes, followed
by further incubation for 24 hours in the absence of ioversol. H89
(10 lmol/L) was added 1 hour before, while beraprost sodium
(1 lmol/L) was included 30 minutes before ioversol treatment. DNA
was isolated and subjected to agarose gel electrophoresis. Lane M, DNA
molecular weight marker VIII (Roche Diagnostics Corporation, Indi-
anapolis, IN, USA); lane 1, intact LLC-PK1 cells; lane 2, 24 hours after
a transient exposure to ioversol; lane 3, ioversol + beraprost sodium;
lane 4, ioversol + beraprost sodium + H89; lane 5, H89. Data were
obtained from at least three independent experiments.
after the removal of ioversol and was more marked at
48 hours (Fig. 4A), as reported previously [3]. The protec-
tive effect of beraprost sodium against ioversol-induced
cell injury was observed as early as 3 hours and lasted
for at least 48 hours. As shown in Figure 4B, the protec-
tive effect of beraprost sodium against ioversol-induced
injury was completely reversed by H89.
Effect of beraprost sodium on ioversol-induced
activation of caspases in LLC-PK1 cells
Ioversol stimulated the activities of caspase-3 and
caspase-9 but not caspase-8, as determined by the
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Fig. 3. Protective effect of beraprost sodium against ioversol-induced injury and the elevation of cellular cyclic adenosine monophosphate (cAMP)
induced by beraprost sodium in LLC-PK1 cells. (A) Cells were exposed to 100 mg iodine/mL ioversol for 30 minutes followed by incubation for
24 hours in the absence of ioversol. Beraprost sodium (10 to 1000 nmol/L) was added 30 minutes before ioversol treatment and included throughout
the experiment. The cell viability was assessed by WST-8 assay. (B) Cells were incubated for 20 minutes with various concentrations of beraprost
sodium in the presence of 0.5 mmol/L 3-isobutyl-l-methylxanthine (IBMX) to prevent the degradation of cAMP produced. The cAMP content
was determined by an enzymatic immunoassay using a cAMP enzyme immunoassay kit. Each column represents the mean ± SEM of four to six
experiments. ∗P < 0.05, ∗∗P < 0.01 vs control.
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Fig. 4. Time course of the protective effect of beraprost sodium (Na) and involvement of protein kinase A (PKA) in the protective effect
of beraprost sodium against ioversol-induced loss of viability in LLC-PK1 cells. (A) Cells were exposed to ioversol (100 mg iodine/mL) for
30 minutes, followed by further incubation for 3 to 48 hoours in the absence of ioversol. Beraprost sodium (1 lmol/L) was included 30 minutes
before ioversol treatment and included throughout the experiment. (B) Cells were exposed to ioversol (100 mg iodine/mL) for 30 minutes, followed
by further incubation for 24 hours in the absence of ioversol. H89 (10 lmol/L) was added 1 hour before, while beraprost sodium (1 lmol/L) was
included 30 minutes before ioversol treatment and included throughout the experiment. Cell viability was assessed by WST-8 assay. Data show the
mean ± SEM of four to six experiments. ∗∗P < 0.01 vs control.
degradation of subtype-specific fluorescence-labeled
peptide substrates (Fig. 5). The ioversol-induced activa-
tion of caspase-3 and caspase-9 was completely blocked
by 1 lmol/L beraprost sodium.
Effect of beraprost sodium on changes in mRNA
expression for bcl-2 and bax induced in LLC-PK1
cells by ioversol
The activity of caspases, particularly caspase-3 and
caspase-9, is considered to be regulated negatively by an
antiapoptotic protein bcl-2 and positively by a proapop-
totic protein bax, thus the ratio of bax/bcl-2 is one of
determinants that cause caspase activation. Ioversol de-
creased the expression for bcl-2 mRNA with a concomi-
tant increase in bax mRNA expression, thereby elevating
the ratio of bax mRNA/bcl-2 mRNA (Fig. 6). Be-
raprost sodium (1 lmol/L) almost completely reversed
the ioversol-induced decrease in bcl-2 mRNA and in-
crease in bax mRNA. This effect of beraprost sodium was
also mediated by PKA, since H89 abolished the action of
beraprost sodium.
Phosphorylation of CREB by beraprost sodium
It has been demonstrated that the expression for bcl-2
is positively regulated by the nuclear factor CREB [20,
21]. CREB is phosphorylated by PKA and the resultant
pCREB readily enters the nucleus and binds to CRE in
the promoter region [22, 23]. As shown in Figure 7B, the
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Fig. 5. Effect of beraprost sodium on ioversol-induced caspase activa-
tion. Cells were exposed to ioversol (100 mg iodine/mL) for 30 minutes
at 37◦C, followed by further incubation for 24 hours at 37◦C in the ab-
sence of ioversol. Beraprost sodium (1 lmol/L) was included 30 minutes
before ioversol treatment and included throughout the experiment. The
reaction was started in the absence or presence of specific caspase in-
hibitors (10 lmol/L), including zDEVD-fmk for caspase-3, zIETD-fmk
for caspase-8, and zLEHD-fmk for caspase-9. The caspase activity was
expressed as nmol of AMC produced per mg protein. Data show the
means ± SEM (N = 4). ∗∗P < 0.01 vs. nontreated.
exposure of LLC-PK1 cells to 1 lmol/L beraprost sodium
markedly increased the number of pCREB immunore-
active cells. DBcAMP (0.3 mmol/L) also enhanced the
pCREB immunoreactivity (Fig. 7D). Both of these ef-
fects of beraprost sodium and DBcAMP were abolished
by H89 (Fig. 7C and E). On the other hand, the action of
DBcAMP was largely diminished after exposure of cells
to ioversol (100 mg iodine/mL for 30 minutes) (Fig. 7F).
DISCUSSION
In our previous report [3], a variety of radiographic
contrast media cause an apoptotic injury in LLC-PK1
cells. In addition, there is no marked difference in the ex-
tent of cell injury among various types of contrast media,
including ionic and nonionic radiographic contrast ma-
terials with different osmolality, thereby suggesting the
lack of involvement of high osmolality or ionicity in the
radiocontrast media-induced renal tubular injury in cul-
ture [3].
We also reported that DBcAMP protects against the
ioversol-induced injury in LLC-PK1 cells through acti-
vation of PKA [3]. Therefore, in the present study, we
determined whether the increase in endogenous cAMP
by stimulating G protein–coupled receptors that posi-
tively linked to adenylate cyclase is effective in protect-
ing against the contrast media-induced renal tubular cell
injury. For this purpose, the effect of a prostacyclin ana-
logue beraprost sodium on the ioversol-induced injury in
LLC-PK1 cells was examined.
Prostacyclin has a potent inhibitory action on platelet
aggregation and vasodilatory action [24, 25]. Prostacyclin
and its analogues stimulate the prostanoid prostacyclin
receptor that coupled to stimulating G protein and adeny-
late cyclase, which leads to the enhancement of cAMP
production in a variety of cells [26, 27].
In the present study, the ioversol-induced loss of cell vi-
ability determined by WST-8 assay or propidium iodide
uptake was remarkably inhibited by beraprost sodium.
It was notable that the protective effect of beraprost
sodium was quite parallel with the elevation of cellular
cAMP content. This protective effect of beraprost sodium
was completely reversed by H89, thereby suggesting that
PKA is involved in this action of beraprost sodium.
On the other hand, the concentration of ioversol
(100 mg iodine/mL) used in the present study was higher
than expected in a clinical setting [28]. We confirmed that
the clinically relevant concentration of ioversol (25 mg io-
dine/mL) caused a slight but significant (P < 0.05) loss of
cell viability in a similar manner to those induced by the
high concentration of this agent, in which the cell injury
was dependent on the caspase-3 [3]. The values in WST-8
assay were 83.0 ± 2.9% of control (mean ± SEM, N = 6)
for ioversol alone and 96.8 ± 3.7% (N = 6) for ioversol
+ 50 lmol/L zDEVD-fmk. Moreover, beraprost sodium
(1 lmol/L) significantly (P < 0.05) reversed the low con-
centration of ioversol-induced cell injury, in which the
value was 96.0 ± 3.6% (N = 6). Therefore, it is likely
that the cellular mechanisms underlying the renal tubu-
lar injury induced by the high concentration (100 mg io-
dine/mL) of ioversol are similar to those induced by the
clinically relevant concentration of the contrast material.
The ioversol-induced cell damage is considered to be
due to apoptosis, since the contrast medium caused a typ-
ical DNA ladder and increased the number of annexin
V–stained cells. Annexin V binds preferentially to phos-
pholipids species such as phosphatidylserine that is nor-
mally absent on the surface of plasma membranes but
translocates to the outer layer of membranes during the
initial stage of apoptosis [29]. Both the DNA fragmenta-
tion and the increase in the number of annexin V–stained
cells induced by ioversol were attenuated by beraprost
sodium in PKA-dependent manner.
On the other hand, annexin V–positive but propidium
iodide–negative cells appeared as early as 1 hour after
a transient exposure to ioversol, thereby indicating the
early stage of apoptosis (data not shown). In addition,
beraprost sodium (1 lmol/L) reversed this early stage of
apoptosis (data not shown). Therefore, it is suggested that
beraprost sodium reverses ioversol-induced cell injury
by inhibiting the apoptosis rather than necrosis. Taken
together, we demonstrated for the first time that a prosta-
cyclin analogue inhibited the apoptotic injury in re-
nal tubular cells induced by the radiographic contrast
medium.
It seems likely that the ioversol-induced apoptosis in
LLC-PK1 cells is dependent on the activation of caspase-
3 and caspase-9, since the activities of both caspase-3 and
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Fig. 6. Effect of beraprost sodium on ioversol-induced changes in the mRNA expression for bcl-2 (A), bax (B), and the ratio of bax mRNA/bcl-2
mRNA (C) in LLC-PK1 cells. Cells were exposed to ioversol (100 mg iodine/mL) for 30 minutes at 37◦C, followed by further incubation for 24 hours
at 37◦C in the absence of ioversol. H89 (10 lmol/L) was added 1 hour before, while beraprost sodium (1 lmol/L) was included 30 minutes before
ioversol treatment and included throughout the experiment. The mRNA was isolated and mRNAs for bcl-2 and bax were measured by reverse
transcription-polymerase chain reaction (RT-PCR). The intensities of PCR products were determined by densitometric analysis. Histograms show
the relative concentration of mRNAs for bcl-2 (A) and bax (B) to b-actin mRNA. Data represent the ± SEM of four experiments. ∗P < 0.05 vs.
ioversol (Steel’s test).
A B C
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Fig. 7. Immunofluorescent stain for nontreated (A) phosphorylated cyclic adenosine monophosphate (cAMP)-responsive element binding protein
(pCREB) showing the protein kinase A (PKA)-dependent CREB phosphorylation by beraprost sodium (B, C) and the reduction in dibutyl cAMP
(DBcAMP)-mediated CREB phosphorylation in LLC-PK1 cells exposed to ioversol (D, E, F). Cells were treated with 1 lmol/L beraprost sodium
or 0.3 mmol/L DBcAMP for 20 minutes with or without prior treatment with 10 lmol/L H89 (30 minutes). (F) Cells were exposed to ioversol (100
mg iodine/mL) for 30 minutes, followed by further incubation for 3 hours in the absence of ioversol. Then, cells were treatment with 0.3 mmol/L
DBcAMP for 20 minutes. The immunofluorescence was detected by a fluorescence microscope under ×100 magnification. Data were obtained from
at least three independent experiments.
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caspase-9 were markedly enhanced by ioversol. More-
over, we reported previously that the inhibitors of these
caspases suppress the cell injury as well as the nuclear
fragmentation induced by ioversol [3]. Caspase-9 is con-
sidered to be a critical apoptosis regulator in a variety
of cells. Activated caspase-9 cleaves procaspase-3 to ac-
tivate caspase-3, which in turn, stimulate the caspase-
dependent deoxyribonuclease (CAD) by inactivating its
inhibitor (ICAD), leading to the chromosomal degrada-
tion [30, 31]. It was noteworthy that beraprost sodium
completely abolished the ioversol-induced enhancement
of caspase-9 and caspase-3 activities.
On the other hand, caspase-9 is activated from
procaspase-9 by cytosolic cytochrome c in the presence of
apoptosis activating factor-1 (Apaf-1) and deoxyadeno-
sine triphosphate (dATP) [32, 33]. The mitochondrial
release of cytochrome c is mediated by bax, a proapop-
totic member of bcl-2 family. It has been demonstrated
that bcl-2 suppresses the caspase-9 activation by inacti-
vating bax and subsequent inhibition of mitochondrial
cytochrome c release [33]. Thus, the ratio of bax/bcl-2 is
considered to be an important determinant of caspase
activation and induction of apoptosis [34, 35].
In the present study, ioversol markedly increased the
expression for bax mRNA while reducing that for bcl-
2 mRNA, resulting in the elevation of the ratio of bax
mRNA/bcl-2 mRNA. These data were consistent with
those reported previously [3]. Notably, the enhancement
of bax mRNA and the reduction in bcl-2 mRNA induced
by ioversol were reversed by beraprost sodium in a man-
ner dependent on the activity of PKA. Therefore, it is
likely that the site of action of beraprost sodium in at-
tenuating ioversol-induced renal tubular cell injury is up-
stream to the expression for bax and/or bcl-2.
It has been demonstrated that cAMP is involved in a
number of physiologic functions via activation of several
signaling pathways, including PKA, CREB, and cAMP-
regulated guanine nucleotide exchange factors [36, 37]. It
has also been shown that PKA promotes the expression
for bcl-2 mRNA by phosphorylating CREB and facili-
tating the binding of this transcription factor to the pro-
moter region (CRE) of bcl-2 gene [38, 39]. Therefore, in
the present study, the effect of beraprost sodium on the
phosphorylation of CREB was examined by an immuno-
histochemical study using monoclonal antibody raised
against pCREB. Both DBcAMP and beraprost sodium
increased the number of pCREB-immunoreactive cells in
PKA-dependent manner. It was also notable that the ex-
posure of cells to ioversol markedly reduced the number
of pCREB-immunoreactive cells after stimulation with
DBcAMP. At present, we do not know the precise mech-
anism underlying the contrast medium-induced inhibi-
tion of CREB phosphorylation. The reduction in CREB
phosphorylation by the contrast medium may be due to
the inhibition of PKA.
Taken together, our present findings suggest that
CREB phosphorylation has a crucial role in the pro-
tective effect of beraprost sodium against the contrast
medium-induced apoptosis in renal tubular cells.
The etiology of contrast medium-induced nephrotoxic-
ity is multiple, which includes the decrease in renal blood
flow and the direct toxic action on renal tubular cells [1, 2].
In the present study, we focused on the effect of beraprost
sodium on the direct toxic action of contrast medium on
renal tubular cells. Therefore, it is still unknown whether
beraprost sodium is effective in contrast medium-induced
nephrotoxicity in vivo. Beraprost sodium is an orally
active prostaglandin I2 (PGI2)analogue used clinically
for the treatment of peripheral arterial disease and pul-
monary arterial hypertension [11]. This agent is reported
to increase the renal blood flow in animals [40] as well as in
humans [41]. Taken together, beraprost sodium may have
a potential in ameliorating contrast medium nephrotoxi-
city in vivo.
CONCLUSION
Beraprost sodium suppressed the ioversol-induced
apoptosis in LLC-PK1 cells by reversing the enhanced
ratio of bax mRNA/bcl-2 mRNA and subsequent inhi-
bition of the activities of caspase-9 and caspase-3. These
effects of beraprost sodium were mediated by the phos-
phorylation of CREB via PKA-dependent mechanism.
Therefore, beraprost sodium may be potentially use-
ful for the prophylaxis of radiographic contrast media
nephrotoxicity.
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